We're Watching (Nasdaq: AMIX) Now—Pull It Up Before the Bell Rings

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Autonomix Medical, Inc. (NASDAQ: AMIX) Just Took The Top Spot On Paul Prescott’s Watchlist This Morning —Tuesday, May 19, 2026 Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Pull Up (AMIX) While It’s Still Early… May 19, 2026 We're Watching (Nasdaq: AMIX) Now—Pull It Up Before the Bell Rings Dear Reader, Street Ideas added Autonomix Medical, Inc. (NASDAQ: AMIX) to the top of its watchlist this Tuesday morning, May 19, 2026, after several factors quickly moved the company onto our radar. With fewer than 12M shares listed in the public float, verified first-in-human clinical proof-of-concept data, and analyst targets from Maxim Group and Ladenburg Thalmann sitting well above current levels, this is the type of setup we pay close attention to early in the session. Analyst Anthony Vendetti of Maxim Group has published a $2 target on (AMIX), while healthcare analyst Jeffrey S. Cohen of Ladenburg Thalmann Co. Inc. holds an $8.20 target. When those three factors converge — a small float, early clinical data, and analyst conviction — it tends to get noticed. That's why (AMIX) is at the top of our radar this morning as the session gets underway. That combination gives (AMIX) a profile worth looking at closely right now. The company is not just another early-stage medical-device name — it is working on a platform designed to identify, treat, and verify overactive nerves through a minimally invasive catheter-based approach. Before we get into the clinical data and broader platform potential, it is important to understand exactly what Autonomix Medical is building. What Is Autonomix Medical? Autonomix Medical, Inc. (NASDAQ: AMIX) is a medical device company focused on transforming the way diseases involving the peripheral nervous system are diagnosed and treated. The company's platform technology centers on a catheter-based microchip sensing array capable of detecting and differentiating neural signals at amplitudes as low as less than 5 microvolts — far below the 100 µV threshold of conventional cardiac sensing tools. That sensitivity gap is precisely what makes this technology first-in-class. The platform follows a "Sense, Treat and Verify" workflow. First, the proprietary ASIC-powered microchip maps overactive nerves through the vessel wall without open surgery. Next, a radiofrequency ablation catheter delivers thermal energy to eliminate target nerves. Finally, the sensing catheter is reinserted to confirm treatment effectiveness in real time — something no competing technology currently enables. (AMIX) holds a portfolio of 120+ issued and pending patents protecting this approach. The company's initial clinical focus is pancreatic cancer pain — a notoriously undertreated condition where patients often face severe, intractable pain as the disease progresses. That is what makes (AMIX) so interesting at this stage: the lead focus is highly specific, but the underlying platform was built with far broader applications in mind. If the company continues showing that it can locate, treat, and verify problematic nerve activity through a catheter-based approach, the implications may extend well beyond pancreatic cancer pain. That is where the bigger picture starts to come into focus. A Market Measured Over $100B The addressable landscape for (AMIX)'s nerve-targeted platform is broad. According to the company's corporate presentation, the combined targeted market potential across chronic pain, cardiovascular, and pulmonary disease exceeds $100B. The global pain management market is sized at approximately $75B, the hypertension treatment market contributes roughly $23B, and the COPD treatment market adds approximately $18B more. Pancreatic cancer — where roughly 66,000 Americans receive a diagnosis annually — serves as (AMIX)'s proof-of-concept lead indication, and success here is designed to unlock the broader platform across dozens of conditions where the peripheral nervous system is implicated. Clinical Data That Commands Attention The results from (AMIX)'s PoC 1 first-in-human study in pancreatic cancer pain are notable. Among 16 femoral access patients who responded to treatment, 100% showed a positive response to the procedure. Pain relief emerged as early as 24 hours post-procedure. At the 3-month post-hoc analysis, the mean VAS pain score fell from a severe-pain baseline of 7.81 down to 2.67 — a 65.6% reduction — more than three times the 20% VAS threshold broadly recognized as clinically significant pain relief. At that same 3-month mark, 100% of responders required zero opi-oid use, and quality-of-life scores showed a 77% improvement. No device- or procedure-related serious adverse events were recorded in that patient group. The PoC 2 follow-on study is now underway with 20 subjects, expanding into additional visceral cancers — including stomach, liver, and bile duct — as well as earlier-stage pancreatic cancer patients. Its findings will inform the design of a U.S. IDE clinical trial, which sits between current PoC work and the company's targeted FDA De Novo submission in 2028. That clinical progress gives (AMIX) a much stronger story than a typical early-stage medical-device profile. Between the first-in-human response data, the active PoC 2 follow-on study, and the longer-term FDA pathway now coming into view, there are several factors converging at once. Here are the seven reasons (AMIX) is standing out to us this morning. Tuesday, May 19, 2026: (AMIX) Is One To Watch This Morning Here’s 7 Reasons Why… 1. Analyst Coverage: Two independent healthcare analysts have published targets on (AMIX), including $2 from Maxim Group and $8.20 from Ladenburg Thalmann. 2. Small Float: With fewer than 12M shares listed as available to the public, (AMIX)’s small float could have the potential for big moves if demand begins to shift. 3. Clinical Response: Early PoC 1 data showed patients treated with (AMIX) experienced a 65.6% reduction in mean VAS pain scores at the 3-month follow-up mark. 4. Pain-Medication Reduction: At the same 3-month checkpoint, 100% of responding patients in the (AMIX) study required no opi-oid-based pain medication following the procedure. 5. Patent Portfolio: More than 120 issued and pending patents support the proprietary nerve-sensing and ablation platform developed by (AMIX). 6. Next Potential Catalyst: PoC 2 enrollment is underway for (AMIX), expanding into additional visceral cancers while helping shape a planned U.S. IDE clinical trial pathway toward a targeted 2028 FDA De Novo submission. 7. First-In-Class: The microchip sensing array used by (AMIX) can detect neural signals below 5 microvolts, far below the approximate 100 µV threshold of conventional cardiac sensing systems. That is why (AMIX) is not just another ticker crossing the screen this morning. The small float, analyst coverage, early clinical response data, patent position, and active PoC 2 study create a setup with several moving parts worth watching closely. When this many details line up at once, it is no wonder why (AMIX) just landed on our radar. Pull Up (AMIX) While It’s Still Early… When you line up the float, analyst coverage, first-in-human data, patent protection, and active PoC 2 enrollment, (AMIX) presents a profile that deserves close attention this morning. The company’s early clinical results — including a 65.6% reduction in mean VAS pain scores and no opi-oid-based pain medication required among responding patients at the 3-month checkpoint — give this developing medical-device story several important pieces to watch as the planned U.S. IDE pathway takes shape. (AMIX) has our full attention this morning. Pull it up before the session gets underway. I may have another update very soon. Sincerely, Paul Prescott Co-Founder & Managing Editor Street Ideas Newsletter   Street-Ideas.com (“Street-Ideas” or “SI” ) is owned by 147 Media LLC, a single member limited liability company. Data is provided from third-party sources and SI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between 147 Media LLC and TD Media LLC, 147 Media LLC has been hired for a period beginning on 05/19/2026 and ending on 05/19/2026 to publicly disseminate information about (AMIX:US) via digital communications. Under this agreement, TD Media LLC has paid 147 Media LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, 147 Media LLC has been paid twenty two thousand five hundred USD (“Funds”). These Funds were part of the twenty five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither 147 Media LLC, TD Media LLC and their member own shares of (AMIX:US). Please see important disclosure information here: https://street-ideas.com/disclosure/amix-Y1lvv/#details

Street Ideas | 6586 W Atlantic Ave, Unit #2086, Delray Beach, FL 33446 Unsubscribe Update Profile | About our service provider Sent by paul@street-ideas.com